Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company developing new therapies for oncology and obesity. The company focuses on innovative scientific approaches to well-understood biological pathways to help people with serious illnesses. Corbus' pipeline includes two main candidates: CRB-701 and CRB-913. CRB-701 is a next-generation antibody drug conjugate (ADC) designed to target Nectin-4 expression on cancer cells, releasing a cytotoxic payload of monomethyl auristatin E (MMAE). In February 2023, Corbus licensed CRB-701 from CSPC Megalith Biopharmaceutical Co. Ltd. for development and commercialization in the U.S., Canada, the European Union (including the European Free Trade Area), the U.K., and Australia. Corbus is conducting a Phase 1/2 study in the U.S. and Europe for patients with advanced solid tumors associated with Nectin-4 expression, with the dose expansion phase currently ongoing. In June 2025, the company began dosing participants in a PD-1 combination arm, administering CRB-701 with Keytruda® (pembrolizumab). The U.S. Food and Drug Administration (FDA) granted fast track designation for CRB-701 for relapsed or refractory metastatic cervical cancer in December 2024, and for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy in September 2025. CSPC is also investigating CRB-701 in a Phase 3 clinical trial for cervical cancer patients in China. CRB-913 is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist intended for the treatment of obesity.